I haven't seen the article, but if accurate, it would mean per patient (if all six doses were administered), not per dose. Please try to link the article.
$250K per patient. But a couple of years ago they had not decided what to charge when starting production on an approved product. People wanting the specials program are raising around $250K.
The combo trial requires only 3 doses over a 1 month period possibly with the idea in mind that the combo with ICLC and especially pembro might create a more robust or longer lasting immune response. There were only 5 doses required with up to 10 made and administered for participation in the Phase 3 trial. Most immune responses will happen before or around 8 weeks after first treatment which is basically the 5 dose schedule. Any 6th dose would be like a booster. Best wishes.